Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

Muhammad Zubair AfzalRima R MercadoKeisuke Shirai

Published in: Journal for immunotherapy of cancer (2018)

We have observed favorable treatment-related outcomes (ORR, DCR, median PFS and median OS) in patients who have received metformin in combination with ICIs without reaching significance, probably, due to small sample size. Hence, large prospective clinical trials are required to study the synergistic effect of metformin in combination with ICIs before it can be recommended as routine additive therapy.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
chronic kidney disease
squamous cell carcinoma
prognostic factors
peritoneal dialysis
cancer therapy
patient reported outcomes
replacement therapy
drug delivery
patient reported
skeletal muscle
smoking cessation
open label